|Bid||66.95 x 1200|
|Ask||71.71 x 1800|
|Day's range||66.79 - 69.03|
|52-week range||39.95 - 87.54|
|Beta (5Y monthly)||1.96|
|PE ratio (TTM)||N/A|
|Earnings date||05 Aug 2020 - 10 Aug 2020|
|Forward dividend & yield||N/A (N/A)|
|1y target est||107.50|
Healthcare investors can look past the development risk. Global Blood Therapeutics (NASDAQ: GBT) crushed analyst estimates when it reported its first-quarter results on May 6. In its first full quarter on the market, Global Blood's sickle cell disease drug Oxbryta posted $14.1 million in net sales.
Global Blood Therapeutics (GBT) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
Global Blood (GBT) delivered earnings and revenue surprises of 18.37% and 268.91%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
Global Blood Therapeutics (NASDAQ: GBT) plans to report its first quarter earnings on Wednesday, May 6. Importantly, investors will see the first full quarter of sales for Oxbryta, the company's recently approved drug for adults and children age 12 and older with sickle cell disease. The Food and Drug Administration (FDA) approved Oxbryta on Nov. 25., three months before the FDA's Priority Review action date for the decision.
Those following along with Global Blood Therapeutics, Inc. (NASDAQ:GBT) will no doubt be intrigued by the recent...
Global Blood Therapeutics, Inc. (NASDAQ:GBT) shareholders might be concerned after seeing the share price drop 12% in...
Shares of Global Blood Therapeutics (GBT) have gained in the past year as its lead candidate voxelotor gets FDA approval for the treatment of SCD in patients aged 12 years or above.
If you're interested in Global Blood Therapeutics, Inc. (NASDAQ:GBT), then you might want to consider its beta (a...
The biotech space of the broad healthcare sector outperformed others in November, courtesy of a series of positive news including study results, regulatory backdrop and deal activities.
The Zacks Analyst Blog Highlights: Intercept, CymaBay, Amgen, Global Blood Therapeutics and ChemoCentryx
Global Blood's (GBT) Oxbryta wins the FDA nod to address sickle cell disease in patients aged 12 years and above. The approval comes three months ahead of schedule.
Global Blood (GBT) incurs a wider-than-expected loss in the third quarter of 2019. Moreover, voxelotor for the treatment of sickle cell disease is under review in the United States.
Trailing twelve-month data shows us that Global Blood Therapeutics, Inc.'s (NASDAQ:GBT) earnings loss has accumulated...
The FDA accepts Global Blood's (GBT) new drug application for voxelotor under priority review to treat sickle cell disease. A decision is expected on Feb 26, 2020.